Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo, Claseprubart, Placebo
Drug · Combination Product
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Boca Raton, Florida • Fayetteville, North Carolina • Houston, Texas
No Longer Available No phase listed Expanded access

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

NCT00704925
Conditions
Lambert Eaton Myasthenic Syndrome
Interventions
3, 4 DAP
Drug
Lead sponsor
David P. Richman, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Sacramento, California
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Interventions
KITE-363, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Newport Beach, California • Palo Alto, California • New York, New York + 2 more
Recruiting No phase listed Observational

MuSK Myasthenia 1000 Study

NCT06259071
Conditions
Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
7 Years to 99 Years
Enrollment
1,000 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, Myasthenia Gravis Generalised, Myasthenia Gravis with Exacerbation (Disorder), Myasthenia Gravis, Adult Form, Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis, Thymectomy, Myasthenia Gravis, Myasthenia Gravis, MuSK
Interventions
Not listed
Lead sponsor
Myasthenia Gravis Foundation of America
Other
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
1
States / cities
Westborough, Massachusetts
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia
Completed No phase listed Observational Results available

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539
Conditions
Neurological Disorder, Autoimmune Diseases
Interventions
Mycophenolate Mofetil, Azathioprine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Palo Alto, California • Miami, Florida • Chicago, Illinois + 12 more
Conditions
Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Conditions
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Active, not recruiting Phase 3 Interventional Results available

Myasthenia Gravis Inebilizumab Trial

NCT04524273
Conditions
Myasthenia Gravis
Interventions
inebilizumab, IV Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
16
States / cities
Orange, California • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more
Conditions
Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Interventions
Social media recruitment, Self-Assessment, Follow-up
Behavioral
Lead sponsor
ZS Associates
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Myasthenia Gravis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more
Conditions
Small Cell Lung Cancer ( SCLC ), Lambert Eaton Myasthenic Syndrome (LEMS)
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more
Conditions
Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)
Interventions
3,4-diaminopyridine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years and older
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
Interventions
Efgartigimod
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Myasthenia Gravis, Myasthenia Gravis, Generalized
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Conditions
Generalized Myasthenia Gravis
Interventions
Whole-body Electrical Muscle Stimulation Exercise
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Columbia, Missouri
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Orange, California • San Francisco, California • Miami, Florida + 9 more
Conditions
Myasthenia Gravis
Interventions
HIZENTRA ®
Drug
Lead sponsor
Mazen Dimachkie, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Kansas City, Kansas • Buffalo, New York + 1 more
Conditions
Myasthenia Gravis, Generalized Myasthenia Gravis
Interventions
Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
Drug · Biological
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 7 more
Conditions
Myasthenia Gravis
Interventions
Oxaloacetate, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
Interventions
anito-cel, Standard Lymphodepletion regimen
Biological · Drug
Lead sponsor
Arcellx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 10 more
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Flower Mound, Texas